NCT06365021

Brief Summary

The goal of this clinical trial is to test the efficacy of Acceptance and Commitment Therapy (ACT) as a psychotherapeutic treatment for patients with Bipolar Disorder (BD). The following questions will be investigated:

  • The efficacy of ACT in reducing depressive symptoms in patients with BD.
  • The efficacy of ACT in improving the quality of life in patients with BD.
  • The efficacy of ACT in improving functionality in patients with BD.
  • The efficacy of ACT in improving sleep quality in patients with BD.
  • The efficacy of ACT in improving psychological flexibility in patients with BD Participants in the clinical group will undergo 12, 2 hours, weekly sessions of Acceptance and Commitment Therapy, in addition to their regular pharmacological treatment. Participants in the control group will undergo 3, 2 hours, weekly sessions of Bipolar Disorder Psychoeducation Therapy, in addition to their regular pharmacological treatment. Scales and assessments will be used to measure study outcomes on 5 different time-points: pre-intervention (month 0), post-intervention (month 3), follow-up 1 (month 6), follow-up 2 (month 9), follow-up 3 (month 12). Mood scales will be assessed every 2 weeks for the duration of treatment and every 4 weeks during the additional 12 week follow-up period. Results will be compared among both groups to assess the effectiveness of Acceptance and Commitment Therapy as an intervention for syndromic and sub-syndromic depression in bipolar disorder.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
6mo left

Started May 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
May 2024Dec 2026

First Submitted

Initial submission to the registry

April 3, 2024

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 15, 2024

Completed
21 days until next milestone

Study Start

First participant enrolled

May 6, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

April 3, 2025

Status Verified

March 1, 2025

Enrollment Period

1.6 years

First QC Date

April 3, 2024

Last Update Submit

March 28, 2025

Conditions

Keywords

Acceptance and Commitment TherapyBipolar DisorderPsychotherapy

Outcome Measures

Primary Outcomes (2)

  • Montgomery-Asberg Depression Scale

    Minimum value: 0 (better) Maximum value: 60 (worse)

    Baseline, during treatment every 2 weeks, post-treatment (week 12), in between assessments every 4 weeks, and follow-ups (6, 9 and 12 months)

  • Young Mania Rating Scale

    Minimum value: 0 (better) Maximum value: 54 (worse)

    Baseline, during treatment every 2 weeks, post-treatment (week 12), in between assessments every 4 weeks, and follow-ups (6, 9 and 12 months)

Secondary Outcomes (4)

  • Functional Assessment Staging Tool

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

  • World Health Organization Quality of Life Brief Scale

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

  • Pittsburgh Sleep Quality Index

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

  • Psychological Flexibility Questionnaire

    Baseline, during treatment weekly, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

Other Outcomes (3)

  • Generalized Anxiety Disorder 7-item Scale

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

  • Medication Recommendation Tracking Form

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

  • Regulatory Satisfaction Alertness Timing Efficiency Duration

    Baseline, post-treatment (week 12), and follow-ups (6, 9 and 12 months)

Study Arms (2)

Acceptance and Commitment Therapy

EXPERIMENTAL

Participants in the clinical group will receive usual pharmacological treatment and undergo a protocol of 12 Acceptance and Commitment Therapy sessions, in group format, during 3 months. The intervention will be held weekly, with an estimated duration of 2 hours for each session, in addition to the participants' regular drug treatment. Scales are administered at the beginning and end of treatment, with follow-ups after 6, 9 and 12 months.

Behavioral: Acceptance and Commitment Therapy

Psychoeducation

EXPERIMENTAL

Participants in the control group will usual pharmacological treatment and 3 sessions of Psychoeducation, in group format. Scales are administered at the beginning and end of treatment, with follow-ups after 6, 9 and 12 months.

Other: Bipolar Disorder Psychoeducation Therapy

Interventions

The ACT protocol for this study was developed by ACT psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 12-session protocol that combines psychoeducation elements, mindfulness exercises, experiential exercises, discussions and group processes, homework assignments, and flexible repertoire modeling and training. The protocol is designed to fit into a single trimester. It covers all the basic aspects of Bipolar Disorder and the six processes of ACT.

Also known as: ACT
Acceptance and Commitment Therapy

The psychoeducation protocol for this study was developed by clinical psychologist Tatiana Cohab Khafif specifically for this study and for Bipolar Patients. It is a 3-session protocol that combines psychoeducation elements, mindfulness exercises, and discussions regarding the main aspects and symptoms of BD. The protocol is designed to fit into a single month, and has a specifically brief format in order for it not to crossover with psychotherapy. It covers all the basic aspects of Bipolar Disorder.

Psychoeducation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of Bipolar Disorder type I and II according to DSM V
  • Presence of depressive symptoms (MADRS\>12)
  • Not undergoing psychotherapy
  • Availability to attend in-person group therapy sessions
  • Signing consent form

You may not qualify if:

  • Organic mental disorder
  • Presence of manic or hypomanic symptoms (YMRS\>12)
  • Currently undergoing psychotherapy (not able to pause during the study)
  • Major medication change in last 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tatiana Cohab Khafif

São Paulo, São Paulo, 01231010, Brazil

RECRUITING

MeSH Terms

Conditions

Bipolar Disorder

Interventions

Acceptance and Commitment Therapy

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Cognitive Behavioral TherapyBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Beny Lafer, MD PhD

    University of Sao Paulo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Beny Lafer, MD PhD

CONTACT

Tatiana C Khafif, Master's degree

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 3, 2024

First Posted

April 15, 2024

Study Start

May 6, 2024

Primary Completion

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

April 3, 2025

Record last verified: 2025-03

Locations